AAVantgarde
Business Services · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Via Visconti Di Modrone Uberto 18, Milan...Phone Number
+39 283991300Website
www.aavantgarde.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About AAVantgarde
AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases. The company’s lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments. With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AAVantgarde your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AAVantgarde recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once AAVantgarde has new funding data
Click to see if AAVantgarde had a recent Job posting/layoffs
Product Launch: Get notified when AAVantgarde launches new products
Congratulate Masked Content for being promoted to Masked Content at AAVantgarde
Check out if AAVantgarde is spiking on competitors!
AAVantgarde, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if AAVantgarde has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at AAVantgarde
Find 2 more new buyers
Company Profile Activity
Activity Insights
AAVantgarde is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AAVantgarde is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AAVantgarde.
AAVantgarde financials insights
Gather financial insights about AAVantgarde, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$65.1M
2025
Series B
$141M
AAVantgarde Tech Stack
A closer look at the technologies used by AAVantgarde
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Funding
Funding
Project
Product Development, Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
AAVantgarde News & Media
AAVantgarde announces completion of recruitment in STELLA natural history study
MILAN, April 21, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced the successful completion of patient recruitment in its STELLA natural history study.AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
MILAN, April 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) focused on large gene delivery via its two proprietary Adeno-Associated Viral (AAV) vector platforms, today announced the appointment of Philip Lao as Senior Vice President of Business Development. Mr. Lao joins the Company’s leadership team and will report to Dr. Natalia Misciattelli, Chief Executive Officer.AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1B This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1BAAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026 in San Francisco, California.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AAVantgarde
Sign Up For FreeTo access detailed company insights
AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases. The company’s lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments. With a strong foundation in translatio... Read More
